Carine San
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Carine San has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Benoit Hosten
Unité Claude Kellershohn, INSERM UMR-S 1144, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010 Paris, France
2 shared publications - Fabienne Dioury
Laboratoire de Génomique Bioinformatique et Chimie Moléculaire, EA 7528, Conservatoire National des Arts et Métiers HESAM Université 2 rue Conté 75003 Paris France
2 shared publications - Laure Sarda-Mantel
Service de Médecine Nucléaire, Hôpital Lariboisière, APHP, Paris
2 shared publications - Marc Port
From the Laboratoire de Génomique, Bioinformatique et Chimie Moléculaire (EA 7528), Equipe Chimie Moléculaire, Conservatoire National des Arts et Métiers, Paris, France
2 shared publications - Nicolas Vignal
Unité Claude Kellershohn, INSERM UMR-S 1144, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), 75010 Paris, France
2 shared publications - Salvatore Cisternino
Université Paris Cité, INSERM UMRS 1144, Optimisation Thérapeutique en Neuropsychopharmacologie
2 shared publications
Latest Publications
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Optimisation de méthodes douces de radiomarquage au fluor-18 pour application en imagerie TEP
La Tomographie par Emission de Positons (TEP) est une technique d'imagerie médicale pratiquée en milieu hospitalier dans les services de médecine nucléaire. Elle est utilisée en cancérologie pour le diagnostic et le suivi thérapeutique de traitements anticancéreux car elle est très sensible pour détecter des tumeurs de petites tailles. A l’heure de la médecine personnalisée, les radiotraceurs à base de biomolécules intéressent grandement les cliniciens. En effet, la spécificité et affinité inégalées des biomolécules pour les organes/tissus pathogènes en font des traceurs de choix. Cependant, la méthode conventionnelle de radiomarquage se fait dans des conditions qui dénaturent ces biomolécules. L’objectif de ce projet est de lever ce verrou et de développer une méthode alternative plus douce basée sur la chimie de coordination de l’espèce gallium-18F peu explorée à ce jour. La méthode alternative proposée ici sera optimisée selon une méthodologie basée sur une solution statistique par Plans d’Expériences. Ce projet relève du domaine de la thérapie ciblée et est à fort potentiel de valorisation ; il vise à développer une nouvelle méthode de préparation de radiotraceurs plus spécifiques des différents types de cancers avec comme finalité ultime un dépistage plus précoce et le développement d’outils de médecine de précision.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Optimisation de méthodes douces de radiomarquage au fluor-18 pour application en imagerie TEP
La Tomographie par Emission de Positons (TEP) est une technique d'imagerie médicale pratiquée en milieu hospitalier dans les services de médecine nucléaire. Elle est utilisée en cancérologie pour le diagnostic et le suivi thérapeutique de traitements anticancéreux car elle est très sensible pour détecter des tumeurs de petites tailles. A l’heure de la médecine personnalisée, les radiotraceurs à base de biomolécules intéressent grandement les cliniciens. En effet, la spécificité et affinité inégalées des biomolécules pour les organes/tissus pathogènes en font des traceurs de choix. Cependant, la méthode conventionnelle de radiomarquage se fait dans des conditions qui dénaturent ces biomolécules. L’objectif de ce projet est de lever ce verrou et de développer une méthode alternative plus douce basée sur la chimie de coordination de l’espèce gallium-18F peu explorée à ce jour. La méthode alternative proposée ici sera optimisée selon une méthodologie basée sur une solution statistique par Plans d’Expériences. Ce projet relève du domaine de la thérapie ciblée et est à fort potentiel de valorisation ; il vise à développer une nouvelle méthode de préparation de radiotraceurs plus spécifiques des différents types de cancers avec comme finalité ultime un dépistage plus précoce et le développement d’outils de médecine de précision.
- Open Access
- 9 November 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (68) , e202403358
Bifunctional Hexadentate Pyclen–Based Chelating Agent for Mild Radiofluorination in Aqueous Solution at Room Temperature with a Ga‐18F Ternary Complex
Positron Emission Tomography (PET) is used in oncology for tumor diagnosis, commonly relying on fluorine‐18 (18F) emission detection. The conventional method of 18F incorporation on to probes by covalent bonding is harsh for sensitive biomolecules, which are nonetheless compounds of choice for the development of targeted probes. This study explores gallium–18F (Ga18F) coordination, a milder alternative method occurring in aqueous media at the final stage of radiosyntheses. Pyclen‐based chelating agents were proposed to capture (GaF) species at room temperature and pH≥5 making the radiofluorination process compatible with heat‐ and acid‐sensitive biomolecules. Highly promising results were obtained with the PC2A–based chelating agent LH2 derived from the new bifunctional PC2A–OAE–NCS compound. The solid‐state structure of GaF(L) was elucidated by X‐ray diffraction and revealed an unconventional heptacoordination of Ga(III). A high radiochemical conversion (RCC) of 86 % was achieved at room temperature, in water at pH 5 within 20 minutes. Stability studies showed the robustness of the GaF(L) complex in aqueous media for at least one day and at least one hour for the radiolabeled analog Ga18F(L). These findings demonstrated that PC2A‐based compounds are chelating agents of choice for (Ga18F) species, suggesting a real technological breakthrough for PET imaging and precision medicine.
- 9 November 2024
- Published by Wiley in Chemistry – A European Journal
- Vol. 30 (68) , e202403358
Open AccessBifunctional Hexadentate Pyclen–Based Chelating Agent for Mild Radiofluorination in Aqueous Solution at Room Temperature with a Ga‐18F Ternary Complex
Positron Emission Tomography (PET) is used in oncology for tumor diagnosis, commonly relying on fluorine‐18 (18F) emission detection. The conventional method of 18F incorporation on to probes by covalent bonding is harsh for sensitive biomolecules, which are nonetheless compounds of choice for the development of targeted probes. This study explores gallium–18F (Ga18F) coordination, a milder alternative method occurring in aqueous media at the final stage of radiosyntheses. Pyclen‐based chelating agents were proposed to capture (GaF) species at room temperature and pH≥5 making the radiofluorination process compatible with heat‐ and acid‐sensitive biomolecules. Highly promising results were obtained with the PC2A–based chelating agent LH2 derived from the new bifunctional PC2A–OAE–NCS compound. The solid‐state structure of GaF(L) was elucidated by X‐ray diffraction and revealed an unconventional heptacoordination of Ga(III). A high radiochemical conversion (RCC) of 86 % was achieved at room temperature, in water at pH 5 within 20 minutes. Stability studies showed the robustness of the GaF(L) complex in aqueous media for at least one day and at least one hour for the radiolabeled analog Ga18F(L). These findings demonstrated that PC2A‐based compounds are chelating agents of choice for (Ga18F) species, suggesting a real technological breakthrough for PET imaging and precision medicine.
- Open Access
- 31 October 2023
- Published by Wiley in Chemistry – A European Journal
- Vol. 29 (71) , e202302745
Optimization of a 1,4,7‐Triazacyclononane‐1,4‐diacetic acid (NODA) Derivative Radiofluorination by Al18F Complexation Using a Design of Experiments Approach
Fluorine‐18 (18F) is the most favorable positron emitter for radiolabeling Positron Emission Tomography (PET) probes. However, conventional 18F labeling through covalent C−F bond formation is challenging, involving multiple steps and stringent conditions unsuitable for sensitive biomolecular probes whose integrity may be altered. Over the past decade, an elegant new approach has been developed involving the coordination of an aluminum fluoride {Al18F} species in aqueous media at a late‐stage of the synthetic process. The objective of this study was to implement this method and to optimize radiolabeling efficiency using a Design of Experiments (DoE). To assess the impact of various experimental parameters on {Al18F} incorporation, a pentadentate chelating agent NODA‐MP‐C4 was prepared as a model compound. This model carried a thiourea function present in the final conjugates resulting from the grafting of the chelating agent onto the probe. The formation of the radioactive complex Al18F‐NODA‐MP‐C4 was studied to achieve the highest radiochemical conversion. A complementary “cold” series study using the natural isotope 19F was also conducted to guide the radiochemical operating conditions. Ultimately, Al18F‐NODA‐MP‐C4 was obtained with a reproducible and satisfactory radiochemical conversion of 79±3.5 % (n=5).
- 31 October 2023
- Published by Wiley in Chemistry – A European Journal
- Vol. 29 (71) , e202302745
Open AccessOptimization of a 1,4,7‐Triazacyclononane‐1,4‐diacetic acid (NODA) Derivative Radiofluorination by Al18F Complexation Using a Design of Experiments Approach
Fluorine‐18 (18F) is the most favorable positron emitter for radiolabeling Positron Emission Tomography (PET) probes. However, conventional 18F labeling through covalent C−F bond formation is challenging, involving multiple steps and stringent conditions unsuitable for sensitive biomolecular probes whose integrity may be altered. Over the past decade, an elegant new approach has been developed involving the coordination of an aluminum fluoride {Al18F} species in aqueous media at a late‐stage of the synthetic process. The objective of this study was to implement this method and to optimize radiolabeling efficiency using a Design of Experiments (DoE). To assess the impact of various experimental parameters on {Al18F} incorporation, a pentadentate chelating agent NODA‐MP‐C4 was prepared as a model compound. This model carried a thiourea function present in the final conjugates resulting from the grafting of the chelating agent onto the probe. The formation of the radioactive complex Al18F‐NODA‐MP‐C4 was studied to achieve the highest radiochemical conversion. A complementary “cold” series study using the natural isotope 19F was also conducted to guide the radiochemical operating conditions. Ultimately, Al18F‐NODA‐MP‐C4 was obtained with a reproducible and satisfactory radiochemical conversion of 79±3.5 % (n=5).
- Open Access
Astroglial Connexin 43 Deficiency Protects against LPS-Induced Neuroinflammation: A TSPO Brain µPET Study with [18F]FEPPA
Astroglial connexin 43 (Cx43) has been recognized as a crucial immunoregulating factor in the brain. Its inactivation leads to a continuous immune recruitment, cytokine expression modification and a specific humoral autoimmune response against the astrocytic extracellular matrix but without brain lesions or cell lysis. To assess the impact of Cx43 deletion on the brain’s inflammatory response, TSPO expression was studied by positron emission tomography (PET) imaging with a specific radioligand, [18F]FEPPA, in basal conditions or upon Lipopolysaccharides (LPS)-induced inflammatory challenge. Astroglial Cx43-deleted mice underwent [18F]FEPPA PET/CT dynamic imaging with or without LPS injection (5 mg/kg) 24 h before imaging. Quantification and pharmacokinetic data modelling with a 2TCM-1K compartment model were performed. After collecting the mice brains, TSPO expression was quantified and localized by Western blot and FISH analysis. We found that astroglial Cx43 deficiency does not significantly alter TSPO expression in the basal state as observed with [18F]FEPPA PET imaging, FISH and Western blot analysis. However, deletion of astrocyte Cx43 abolishes the LPS-induced TSPO increase. Autoimmune encephalopathy observed in astroglial Cx43-deleted mice does not involve TSPO overexpression. Consistent with previous studies showing a unique inflammatory status in the absence of astrocyte Cx43, we show that a deficient expression of astrocytic Cx43 protects the animals from LPS-induced neuroinflammation as addressed by TSPO expression.
Open AccessAstroglial Connexin 43 Deficiency Protects against LPS-Induced Neuroinflammation: A TSPO Brain µPET Study with [18F]FEPPA
Astroglial connexin 43 (Cx43) has been recognized as a crucial immunoregulating factor in the brain. Its inactivation leads to a continuous immune recruitment, cytokine expression modification and a specific humoral autoimmune response against the astrocytic extracellular matrix but without brain lesions or cell lysis. To assess the impact of Cx43 deletion on the brain’s inflammatory response, TSPO expression was studied by positron emission tomography (PET) imaging with a specific radioligand, [18F]FEPPA, in basal conditions or upon Lipopolysaccharides (LPS)-induced inflammatory challenge. Astroglial Cx43-deleted mice underwent [18F]FEPPA PET/CT dynamic imaging with or without LPS injection (5 mg/kg) 24 h before imaging. Quantification and pharmacokinetic data modelling with a 2TCM-1K compartment model were performed. After collecting the mice brains, TSPO expression was quantified and localized by Western blot and FISH analysis. We found that astroglial Cx43 deficiency does not significantly alter TSPO expression in the basal state as observed with [18F]FEPPA PET imaging, FISH and Western blot analysis. However, deletion of astrocyte Cx43 abolishes the LPS-induced TSPO increase. Autoimmune encephalopathy observed in astroglial Cx43-deleted mice does not involve TSPO overexpression. Consistent with previous studies showing a unique inflammatory status in the absence of astrocyte Cx43, we show that a deficient expression of astrocytic Cx43 protects the animals from LPS-induced neuroinflammation as addressed by TSPO expression.
- Open Access
[18F]FEPPA a TSPO Radioligand: Optimized Radiosynthesis and Evaluation as a PET Radiotracer for Brain Inflammation in a Peripheral LPS-Injected Mouse Model
[18F]FEPPA is a specific ligand for the translocator protein of 18 kDa (TSPO) used as a positron emission tomography (PET) biomarker for glial activation and neuroinflammation. [18F]FEPPA radiosynthesis was optimized to assess in a mouse model the cerebral inflammation induced by an intraperitoneal injection of Salmonella enterica serovar Typhimurium lipopolysaccharides (LPS; 5 mg/kg) 24 h before PET imaging. [18F]FEPPA was synthesized by nucleophilic substitution (90 °C, 10 min) with tosylated precursor, followed by improved semi-preparative HPLC purification (retention time 14 min). [18F]FEPPA radiosynthesis were carried out in 55 min (from EOB). The non-decay corrected radiochemical yield were 34 ± 2% (n = 17), and the radiochemical purity greater than 99%, with a molar activity of 198 ± 125 GBq/µmol at the end of synthesis. Western blot analysis demonstrated a 2.2-fold increase in TSPO brain expression in the LPS treated mice compared to controls. This was consistent with the significant increase of [18F]FEPPA brain total volume of distribution (VT) estimated with pharmacokinetic modelling. In conclusion, [18F]FEPPA radiosynthesis was implemented with high yields. The new purification/formulation with only class 3 solvents is more suitable for in vivo studies.
Open Access[18F]FEPPA a TSPO Radioligand: Optimized Radiosynthesis and Evaluation as a PET Radiotracer for Brain Inflammation in a Peripheral LPS-Injected Mouse Model
[18F]FEPPA is a specific ligand for the translocator protein of 18 kDa (TSPO) used as a positron emission tomography (PET) biomarker for glial activation and neuroinflammation. [18F]FEPPA radiosynthesis was optimized to assess in a mouse model the cerebral inflammation induced by an intraperitoneal injection of Salmonella enterica serovar Typhimurium lipopolysaccharides (LPS; 5 mg/kg) 24 h before PET imaging. [18F]FEPPA was synthesized by nucleophilic substitution (90 °C, 10 min) with tosylated precursor, followed by improved semi-preparative HPLC purification (retention time 14 min). [18F]FEPPA radiosynthesis were carried out in 55 min (from EOB). The non-decay corrected radiochemical yield were 34 ± 2% (n = 17), and the radiochemical purity greater than 99%, with a molar activity of 198 ± 125 GBq/µmol at the end of synthesis. Western blot analysis demonstrated a 2.2-fold increase in TSPO brain expression in the LPS treated mice compared to controls. This was consistent with the significant increase of [18F]FEPPA brain total volume of distribution (VT) estimated with pharmacokinetic modelling. In conclusion, [18F]FEPPA radiosynthesis was implemented with high yields. The new purification/formulation with only class 3 solvents is more suitable for in vivo studies.